Physician profile
Lisa Hatcher
NPI 1932164621
$790.33
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $39.65 · 2021: $127 · 2022: $382.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $177.70 | 2021-2022 | |
| Abbott Laboratories | $122.50 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.34 | 2021-2022 | |
| Novo Nordisk INC | $52.08 | 2019-2022 | |
| Lilly USA, LLC | $49.69 | 2020-2022 | |
| Amgen INC. | $44.63 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $43.55 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.49 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $25.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $23.87 | 2019-2022 | |
| Amarin Pharma, INC. | $21.80 | 2022 | |
| Merck Sharp & Dohme LLC | $17.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.52 | 2021 | |
| Sobi, INC | $14.68 | 2019 | |
| Therapeuticsmd, INC. | $14.36 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $13.77 | 2022 | |
| Allergan, INC. | $13.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.15 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Hatcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.